A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects With Severe Sepsis and Coagulopathy

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects With Severe Sepsis and Coagulopathy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Thrombomodulin alfa (Primary)
  • Indications Disseminated intravascular coagulation; Sepsis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Asahi Kasei Pharma America Corp
  • Most Recent Events

    • 21 Jan 2016 Planned End Date changed from 1 Mar 2018 to 1 Sep 2018 as reported by ClinicalTrials.gov record.
    • 21 Jan 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
    • 02 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2016 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top